NRG Oncology's GU007 (NADIR): A randomized phase II trial of niraparib with standard combination androgen deprivation therapy (ADT) and radiotherapy (RT) in high-risk prostate cancer (PC) (with initial phase I)

被引：4
|
作者：
Zumsteg, Z. [1 ]
Karrison, T. [2 ]
Michaelson, M. D. [3 ]
Tran, P. [4 ]
Kudchadker, R. [5 ]
Feng, F. [6 ]
机构：
[1] Cedars Sinai Med Ctr, Dept Radiat Oncol, Los Angeles, CA 90048 USA
[2] Univ Chicago, Dept Publ Hlth Sci, Chicago, IL 60637 USA
[3] Harvard Med Sch, Dept Med Oncol, Massachusetts Gen Hosp, Boston, MA 02115 USA
[4] Johns Hopkins, Dept Radiat Oncol, Baltimore, MD USA
[5] MD Anderson, Dept Radiat Oncol, Houston, TX USA
[6] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.2083
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
689TiP
引用
收藏
页码：S546 / S546
页数：1
相关论文
共 50 条
  • [1] Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial
    Nabid, Abdenour
    Carrier, Nathalie
    Martin, Andre-Guy
    Bahary, Jean-Paul
    Lemaire, Celine
    Vass, Sylvie
    Bahoric, Boris
    Archambault, Robert
    Vincent, Francois
    Bettahar, Redouane
    Duclos, Marie
    Garant, Marie-Pierre
    Souhami, Luis
    EUROPEAN UROLOGY, 2018, 74 (04) : 432 - 441
  • [2] Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) vs. Dose Escalated Radiation Therapy and Enhanced ADT with TAK-700 for Men with High-Risk Prostate Cancer (NRG Oncology/RTOG 1115)
    Michaelson, D.
    Dignam, J. J.
    Hamstra, D. A.
    Bachand, F.
    Master, V.
    Bruner, D. W.
    Torres, M.
    Saylor, P. J.
    Wallace, R. E.
    Vapiwala, N.
    Efstathiou, J. A.
    Roach, M., III
    Rosenthal, S. A.
    Raben, A.
    Morgan, S. C.
    Kavadi, V. S.
    Spratt, D. E.
    Michalski, J. M.
    Rodgers, J.
    Sandler, H. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S67 - S68
  • [3] Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial
    Rosenthal, Seth A.
    Hu, Chen
    Sartor, Oliver
    Gomella, Leonard G.
    Amin, Mahul B.
    Purdy, James
    Michalski, Jeff M.
    Garzotto, Mark G.
    Pervez, Nadeem
    Balogh, Alexander G.
    Rodrigues, George B.
    Souhami, Luis
    Reaume, M. Neil
    Williams, Scott G.
    Hannan, Raquibul
    Horwitz, Eric M.
    Raben, Adam
    Peters, Christopher A.
    Feng, Felix Y.
    Shipley, William U.
    Sandler, Howard M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (14) : 1159 - +
  • [4] Phase II trial enzalutamide and androgen deprivation therapy (ADT) with salvage radiation in men with high risk PSA recurrent prostate cancer (PC): The STREAM trial.
    Armstrong, Andrew J.
    Bitting, Rhonda L.
    Healy, Patrick
    George, Daniel J.
    Kim, Sung
    Mayer, Tina M.
    Winters, Carolyn
    Riggan, Colleen
    Rasmussen, Julia
    Wilder, Rhonda
    Anand, Monika
    Stein, Mark N.
    Frizzell, Bart
    Harrison, Michael Roger
    Zhang, Tian
    Lee, W. Robert
    Wu, Yuan
    Koontz, Bridget F.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [5] Re: Androgen deprivation therapy and radiotherapy in intermediate risk prostate cancer: A randomized phase III trial
    Guler, Ozan Cem
    Onal, Cem
    EUROPEAN JOURNAL OF CANCER, 2022, 167 : 164 - 165
  • [6] Phase II trial of external radiotherapy, brachytherapy, androgen deprivation and docetaxel chemotherapy for high-risk, localized prostate cancer
    DiBiase, SJ
    Dawson, N
    Kwok, Y
    Kataria, R
    Hussain, A
    Nagda, S
    Bangalore, M
    Amin, P
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S296 - S297
  • [7] A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer
    Robert Amato
    Mika Stepankiw
    Patricia Gonzales
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1629 - 1634
  • [8] Phase I/IIa trial of androgen deprivation therapy, external beam radiotherapy, and stereotactic body radiotherapy boost for high-risk prostate cancer (ADEBAR)
    Kim, Yeon Joo
    Ahn, Hanjong
    Kim, Choung-Soo
    Kim, Young Seok
    RADIATION ONCOLOGY, 2020, 15 (01)
  • [9] Phase I/IIa trial of androgen deprivation therapy, external beam radiotherapy, and stereotactic body radiotherapy boost for high-risk prostate cancer (ADEBAR)
    Yeon Joo Kim
    Hanjong Ahn
    Choung-Soo Kim
    Young Seok Kim
    Radiation Oncology, 15
  • [10] A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer
    Amato, Robert
    Stepankiw, Mika
    Gonzales, Patricia
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (06) : 1629 - 1634
12345